share_log

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K：外國發行人報告
美股SEC公告 ·  04/12 08:02
Moomoo AI 已提取核心訊息
Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.
Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.
處於發展階段的企業Alterity Therapeutics已於2024年4月12日成功舉行了特別股東大會（EGM），所有決議均以投票方式獲得通過。該會議在澳大利亞墨爾本舉行，也與該公司在美國舊金山的業務有關，各項未公開的決議獲得批准。股東特別大會的結果符合澳大利亞證券交易所上市規則3.13.2和2001年《公司法》第251AA（1）條。已根據監管要求提供了詳細的代理和投票結果。該公司在澳大利亞證券交易所和納斯達克上市，已將該報告納入其美國證券交易委員會的文件中，包括其關於S-8和F-3表格的註冊聲明。
處於發展階段的企業Alterity Therapeutics已於2024年4月12日成功舉行了特別股東大會（EGM），所有決議均以投票方式獲得通過。該會議在澳大利亞墨爾本舉行，也與該公司在美國舊金山的業務有關，各項未公開的決議獲得批准。股東特別大會的結果符合澳大利亞證券交易所上市規則3.13.2和2001年《公司法》第251AA（1）條。已根據監管要求提供了詳細的代理和投票結果。該公司在澳大利亞證券交易所和納斯達克上市，已將該報告納入其美國證券交易委員會的文件中，包括其關於S-8和F-3表格的註冊聲明。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息